Skip to main content
Erschienen in: European Child & Adolescent Psychiatry 2/2011

01.02.2011 | Review Article

Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry

verfasst von: Celso Arango

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The DSM-5 task force on schizophrenia and psychotic disorders have recently proposed to include attenuated psychotic symptoms syndrome as a disorder not currently listed in DSM-IV-TR, either in the main manual or in an Appendix for further research. One of the potential benefits of including this diagnosis in DSM-5 is to identify persons at high risk of developing psychotic disorders to prevent the appearance of these disorders or lead to disorders with a better prognosis. One of the challenges applying the criteria proposed to the pediatric population is the difficulty in defining “attenuated” in the same way and it is done with adults. The threshold for psychosis may be lower in children and, therefore, what is attenuated in adults may be fully present, although transient, in paediatric population. Other potential risks are a lower threshold for prescribing antipsychotics without clear evidence and whether the help-seeking behaviour criterion will be applied to the patients and/or the parents.
Literatur
1.
Zurück zum Zitat NIMH (2007) Transformative neurodevelopmental research in mental illness. Report of the national advisory mental health council’s workgroup NIMH (2007) Transformative neurodevelopmental research in mental illness. Report of the national advisory mental health council’s workgroup
4.
Zurück zum Zitat Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkotter J (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36(1):182–191. doi:10.1093/schbul/sbn072 CrossRefPubMed Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkotter J (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36(1):182–191. doi:10.​1093/​schbul/​sbn072 CrossRefPubMed
5.
Zurück zum Zitat McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rossler A, Klosterkotter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR (2009) Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 70(9):1206–1212. doi:10.4088/JCP.08r04472 CrossRefPubMed McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rossler A, Klosterkotter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR (2009) Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 70(9):1206–1212. doi:10.​4088/​JCP.​08r04472 CrossRefPubMed
6.
Zurück zum Zitat Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, Ross M, Kelly D, Baker K, Conus P, Amminger P, Trumpler F, Yun Y, Lim M, McNab C, Yung AR, McGorry PD (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43(9):818–829. doi:10.1080/00048670903107625 CrossRefPubMed Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, Ross M, Kelly D, Baker K, Conus P, Amminger P, Trumpler F, Yun Y, Lim M, McNab C, Yung AR, McGorry PD (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43(9):818–829. doi:10.​1080/​0004867090310762​5 CrossRefPubMed
7.
Zurück zum Zitat McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163(5):790–799. doi:163/5/790[pii]10.1176/appi.ajp.163.5.790 CrossRefPubMed McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163(5):790–799. doi:163/​5/​790[pii]10.​1176/​appi.​ajp.​163.​5.​790 CrossRefPubMed
10.
Zurück zum Zitat Freeman LN, Poznanski EO, Grossman JA, Buchsbaum YY, Banegas ME (1985) Psychotic and depressed children: a new entity. J Am Acad Child Psychiatry 24(1):95–102CrossRefPubMed Freeman LN, Poznanski EO, Grossman JA, Buchsbaum YY, Banegas ME (1985) Psychotic and depressed children: a new entity. J Am Acad Child Psychiatry 24(1):95–102CrossRefPubMed
12.
Zurück zum Zitat van Os J, Hanssen M, Bijl RV, Vollebergh W (2001) Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 58(7):663–668. doi:yoa20258[pii] CrossRefPubMed van Os J, Hanssen M, Bijl RV, Vollebergh W (2001) Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 58(7):663–668. doi:yoa20258[pii] CrossRefPubMed
15.
Zurück zum Zitat Horwood J, Salvi G, Thomas K, Duffy L, Gunnell D, Hollis C, Lewis G, Menezes P, Thompson A, Wolke D, Zammit S, Harrison G (2008) Iq and non-clinical psychotic symptoms in 12-year-olds: results from the alspac birth cohort. Br J Psychiatry 193(3):185–191. doi:10.1192/bjp.bp.108.051904 CrossRefPubMed Horwood J, Salvi G, Thomas K, Duffy L, Gunnell D, Hollis C, Lewis G, Menezes P, Thompson A, Wolke D, Zammit S, Harrison G (2008) Iq and non-clinical psychotic symptoms in 12-year-olds: results from the alspac birth cohort. Br J Psychiatry 193(3):185–191. doi:10.​1192/​bjp.​bp.​108.​051904 CrossRefPubMed
18.
Zurück zum Zitat Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombin I, Moreno D (2009) Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18(7):418–428. doi:10.1007/s00787-009-0749-5 CrossRefPubMed Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombin I, Moreno D (2009) Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18(7):418–428. doi:10.​1007/​s00787-009-0749-5 CrossRefPubMed
Metadaten
Titel
Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry
verfasst von
Celso Arango
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
European Child & Adolescent Psychiatry / Ausgabe 2/2011
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-010-0144-2

Weitere Artikel der Ausgabe 2/2011

European Child & Adolescent Psychiatry 2/2011 Zur Ausgabe

Original Contribution

Non-suicidal self-injury

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.